Teriflunomide
- Generic Name
- Teriflunomide
- Brand Names
- Aubagio, Teriflunomide Accord, Teriflunomide Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C12H9F3N2O2
- CAS Number
- 163451-81-8
- Unique Ingredient Identifier
- 1C058IKG3B
- Background
Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.
- Indication
Used in the treatment of relapsing forms of multiple sclerosis (MS).
- Associated Conditions
- Multiple Sclerosis
Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Biocad
- Target Recruit Count
- 271
- Registration Number
- NCT04056897
- Locations
- 🇷🇺
State Budgetary Healthcare Institution of Nizhny Novgorod region "Regional Clinical Hospital N.A. Semashko, Nizhny Novgorod", Nizhny Novgorod, Russian Federation
To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis
- First Posted Date
- 2019-02-27
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 121
- Registration Number
- NCT03856619
- Locations
- 🇮🇳
Investigational Site Number :026, Gurgaon, India
🇮🇳Investigational Site Number :014, Pune, India
🇮🇳Investigational Site Number :007, Gurgaon, India
Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio)
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- McGill University
- Target Recruit Count
- 24
- Registration Number
- NCT03561402
- Locations
- 🇨🇦
Department of Pathology, Montréal, Quebec, Canada
Teriflunomide Tecfidera LMCE
- First Posted Date
- 2018-05-16
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- University at Buffalo
- Target Recruit Count
- 120
- Registration Number
- NCT03526224
- Locations
- 🇺🇸
Buffalo Neuroimaging Analysis Center, Buffalo, New York, United States
Mechanistic Studies of Teriflunomide in RRMS
- First Posted Date
- 2018-03-14
- Last Posted Date
- 2022-12-27
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 30
- Registration Number
- NCT03464448
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )
- Conditions
- Relapsing Multiple Sclerosis (RMS)
- Interventions
- First Posted Date
- 2017-09-11
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 549
- Registration Number
- NCT03277261
- Locations
- 🇺🇸
TG Therapeutics RMS Investigational Site, Round Rock, Texas, United States
🇺🇸TG Therapeutics RMS Investigational Trial Site, Dallas, Texas, United States
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)
- Conditions
- Relapsing Multiple Sclerosis (RMS)
- Interventions
- First Posted Date
- 2017-09-11
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 545
- Registration Number
- NCT03277248
- Locations
- 🇺🇸
TG Therapeutics RMS Investigational Trial site, Seattle, Washington, United States
🇺🇸TG Therapeutics RMS Investigational Trial Site, Pittsburgh, Pennsylvania, United States
An Observational Study on Teriflunomide-exposed Pregnancies
- First Posted Date
- 2017-06-26
- Last Posted Date
- 2023-08-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 220
- Registration Number
- NCT03198351
- Locations
- 🇺🇸
University of California at San Diego-Site Number:001, San Diego, California, United States
🇨🇦Investigational Site Number :002, Canada, Canada
Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2017-04-21
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Centre Hospitalier Universitaire de Nice
- Target Recruit Count
- 125
- Registration Number
- NCT03122652
- Locations
- 🇫🇷
CHRU de Montpellier, Montpellier, France
🇹🇷Mustafa Kemal University, Antakya, Turkey
🇫🇷CHU de Bordeaux, Bordeaux, France
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Drug: Teriflunomide-matching placebo capsulesDrug: Matching placebo of ofatumumab subcutaneous injections
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2021-10-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 930
- Registration Number
- NCT02792218
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.